Begelomab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Begelomab
Accession Number
DB13241
Type
Biotech
Groups
Experimental, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
360N6PY2A1
CAS number
1403744-56-8

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Begelomab.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Begelomab.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Begelomab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Begelomab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Begelomab.Approved
FingolimodBegelomab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Begelomab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Begelomab.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Begelomab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Begelomab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Begelomab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Begelomab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Begelomab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Begelomab is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Begelomab.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Begelomab is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Begelomab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Begelomab.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Begelomab.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Begelomab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Begelomab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Begelomab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Begelomab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Begelomab.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Begelomab.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Begelomab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Begelomab.Investigational
TofacitinibBegelomab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Begelomab.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Begelomab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Begelomab.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
ATC Codes
L04AA35 — Begelomab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on January 05, 2018 13:27